Clinical trials: Microvascular Angina
Hypertension, Cardiovascular Diseases
Cardiovascular Disease Risk Factors in Chinese American Immigrants
The Chinese population is currently the fastest growing ethnic group in New York City (NYC). Research has shown that Chinese immigrants living in NYC have higher rates of cardiovascular disease (CVD) than individuals in China.
- Conditions
- Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
- Trial name
- CHA-CHA (NCT00362128)
- Where
- United States
- Volunteers
- 2,072 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with…
- Trial name
- LIBERTY-HCM (NCT02291237)
- Testing
- Eleclazine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
Wiskott-Aldrich Syndrome, Thrombocytopenia
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
- Conditions
- Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
- Trial name
- WAS (NCT00909363)
- Testing
- Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Diabetes, Metabolic Syndrome x
Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
This study will compare how well a combination of borage and echium oils will reduce inflammation compared to fish oils and placebo oil in subjects that are diabetic or have metabolic syndrome.
- Trial name
- NCT01145066
- Testing
- borage/echium oil combination, fish oil, corn oil
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
Microvascular Coronary Artery Disease
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically…
- Trial name
- NCT03236311
- Testing
- SAR407899, Adenosine, Regadenoson
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 10 people
- Sponsor
- Sanofi
Metabolic Syndrome X, Overweight
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455325)
- Testing
- Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine
NLRC4-MAS, XIAP Deficiency
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nucleotide-binding oligomerization domain, leucine-rich repeat and…
- Trial name
- NCT03113760
- Testing
- Tadekinig alfa, 0.9% sodium chloride
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- AB2 Bio Ltd.
Metabolic Syndrome X, Overweight
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455403)
- Testing
- Chloroquine
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Washington University School of Medicine
Metabolic Syndrome X, Prediabetic State
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
The relationship between obesity and insulin resistance is known, however the mechanism(s) associating obesity with insulin resistance is not well understood.
- Trial name
- NCT00470262
- Testing
- Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Microvascular Angina
Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Women have less significant blockages of coronary arteries, however have greater symptoms and worse outcomes compared to their age-matched male counterparts.
- Trial name
- NIRVANA (NCT01665508)
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Metabolic Syndrome X
Inflammation and the Metabolic Syndrome in Humans
People who are overweight are at increased risk of heart disease. Being overweight and having heart disease are linked in that both involve inflammation.
- Trial name
- LPS (NCT00954824)
- Testing
- Endotoxin (LPS)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Metabolic Syndrome X
Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease. Banaba has shown evidence that has on metabolic syndrome, insulin sensitivity and insulin secretion.
- Trial name
- NCT02767869
- Testing
- Banaba
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Diabetes Mellitus, Metabolic Syndrome X
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily.
- Conditions
- Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
- Trial name
- STOPCAP (NCT00166036)
- Testing
- Atorvastatin, Pravastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Metabolic Syndrome X
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women.
- Trial name
- NCT00608465
- Testing
- Eplerenone, Ramipril
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Cardiovascular Diseases, Metabolic Syndrome X
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis
- Trial name
- PAD (NCT00272311)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Florida Atlantic University
Morbid Obesity, Metabolic Syndrome X
Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity
Bariatric surgery is the most effective treatment for morbid obesity. Roux-en-Y gastric bypass (RYGB) is a bariatric procedure with known safety and effectiveness.
- Conditions
- Morbid Obesity, Metabolic Syndrome X, Diabetes Mellitus, Dyslipidemia
- Trial name
- NCT01806506
- Testing
- Laparoscopic sleeve gastrectomy, Roux-en-Y Gastric Bypass
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Medical University of Warsaw
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Metabolic Syndrome X
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Ezetimibe has been shown to inhibit cholesterol absorption and several lines of evidence from in vitro systems and animal models suggest that this effect is associated with an increase in low-density lipoprotein (LDL) receptor…
- Trial name
- EZEmRNA (NCT01849068)
- Testing
- Ezetimibe
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Laval University